tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2022 Feb;58:103399.
doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sedat Sen[SUP] 1 [/SUP], Asli Tuncer[SUP] 2 [/SUP], Serkan Ozakbas[SUP] 3 [/SUP], Cihat Uzunkopru[SUP] 4 [/SUP], Cavid Baba[SUP] 3 [/SUP], Serkan Demir[SUP] 5 [/SUP], Yesim Beckmann[SUP] 4 [/SUP], Haluk Gumus[SUP] 6 [/SUP], Gokhan Arslan[SUP] 7 [/SUP], Ahmet Kasim Kilic[SUP] 8 [/SUP], Ayse Altintas[SUP] 9 [/SUP], Nur Yuceyar[SUP] 10 [/SUP], Omer Faruk Turan[SUP] 11 [/SUP], Melih Tutuncu[SUP] 12 [/SUP], Murat Terzi[SUP] 7 [/SUP], Pinar Acar[SUP] 2 [/SUP], Sena Destan Bunul[SUP] 13 [/SUP], Belgin Petek Balci[SUP] 14 [/SUP], Levent Sinan Bir[SUP] 15 [/SUP], Mesrure Koseoglu[SUP] 16 [/SUP], Semra Mungan[SUP] 17 [/SUP], Tuncay Gunduz[SUP] 18 [/SUP], Ipek Gungor Dogan[SUP] 5 [/SUP], Dilcan Kotan[SUP] 19 [/SUP], Ugur Uygunoglu[SUP] 12 [/SUP], Ozgul Ekmekci[SUP] 10 [/SUP], Meltem Demirkiran[SUP] 20 [/SUP], Ozden Kamisli[SUP] 21 [/SUP], Sibel Canbaz Kabay[SUP] 22 [/SUP], Yusuf Tamam[SUP] 23 [/SUP], Sami Omerhoca[SUP] 24 [/SUP], Serhan Sevim[SUP] 25 [/SUP], Sibel Guler[SUP] 26 [/SUP], Murat Kurtuncu[SUP] 18 [/SUP], Husnu Efendi[SUP] 13 [/SUP], Rana Karabudak[SUP] 2 [/SUP], Aksel Siva[SUP] 27 [/SUP]
Affiliations
Abstract
Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known.
Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed.
Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found.
Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.
Keywords: Coronavirus; Disease modifying treatment; Myelin oligodendrocyte glycoprotein antibody-associated disorders; Neuromyelitis optica spectrum disorders; SARS-CoV-2.
. 2022 Feb;58:103399.
doi: 10.1016/j.msard.2021.103399. Epub 2021 Nov 19.
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sedat Sen[SUP] 1 [/SUP], Asli Tuncer[SUP] 2 [/SUP], Serkan Ozakbas[SUP] 3 [/SUP], Cihat Uzunkopru[SUP] 4 [/SUP], Cavid Baba[SUP] 3 [/SUP], Serkan Demir[SUP] 5 [/SUP], Yesim Beckmann[SUP] 4 [/SUP], Haluk Gumus[SUP] 6 [/SUP], Gokhan Arslan[SUP] 7 [/SUP], Ahmet Kasim Kilic[SUP] 8 [/SUP], Ayse Altintas[SUP] 9 [/SUP], Nur Yuceyar[SUP] 10 [/SUP], Omer Faruk Turan[SUP] 11 [/SUP], Melih Tutuncu[SUP] 12 [/SUP], Murat Terzi[SUP] 7 [/SUP], Pinar Acar[SUP] 2 [/SUP], Sena Destan Bunul[SUP] 13 [/SUP], Belgin Petek Balci[SUP] 14 [/SUP], Levent Sinan Bir[SUP] 15 [/SUP], Mesrure Koseoglu[SUP] 16 [/SUP], Semra Mungan[SUP] 17 [/SUP], Tuncay Gunduz[SUP] 18 [/SUP], Ipek Gungor Dogan[SUP] 5 [/SUP], Dilcan Kotan[SUP] 19 [/SUP], Ugur Uygunoglu[SUP] 12 [/SUP], Ozgul Ekmekci[SUP] 10 [/SUP], Meltem Demirkiran[SUP] 20 [/SUP], Ozden Kamisli[SUP] 21 [/SUP], Sibel Canbaz Kabay[SUP] 22 [/SUP], Yusuf Tamam[SUP] 23 [/SUP], Sami Omerhoca[SUP] 24 [/SUP], Serhan Sevim[SUP] 25 [/SUP], Sibel Guler[SUP] 26 [/SUP], Murat Kurtuncu[SUP] 18 [/SUP], Husnu Efendi[SUP] 13 [/SUP], Rana Karabudak[SUP] 2 [/SUP], Aksel Siva[SUP] 27 [/SUP]
Affiliations
- PMID: 35216782
- DOI: 10.1016/j.msard.2021.103399
Abstract
Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known.
Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed.
Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found.
Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection.
Keywords: Coronavirus; Disease modifying treatment; Myelin oligodendrocyte glycoprotein antibody-associated disorders; Neuromyelitis optica spectrum disorders; SARS-CoV-2.